BDX vs URGN · P/E 34, rev $21.84B vs rev $123.4M
Becton Dickinson and Company (BDX) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. URGN currently screens at market cap $1.61B.
Not investment advice. Open the BDX and URGN stock pages for the full models.
Not investment advice.